CareDx Q1 2024 Adj EPS $(0.03) Beats $(0.21) Estimate, Sales $72.049M Beat $63.140M Estimate
Portfolio Pulse from Benzinga Newsdesk
CareDx (NASDAQ:CDNA) reported Q1 2024 adjusted EPS of $(0.03), surpassing the $(0.21) estimate, and sales of $72.049M, beating the $63.140M estimate. This represents an 85.71% beat on EPS estimates and a 14.11% beat on sales estimates, despite a 6.75% decrease in sales compared to the same period last year.
May 09, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CareDx reported a significant beat on both EPS and sales estimates for Q1 2024, with adjusted EPS of $(0.03) against a $(0.21) estimate and sales of $72.049M against a $63.140M estimate.
CareDx's significant beat on both EPS and sales estimates for Q1 2024 indicates strong financial performance and operational efficiency, likely leading to positive investor sentiment and potential short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100